Joseph Catanzaro's Stock Ratings

Piper Sandler Analyst

Joseph Catanzaro is an analyst at Piper Sandler. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

-3.37%

Smart Score

46.5%

Overall Average Return Percentile

30th

Number of Ratings

57
Buy NowGet Alert
05/16/2024CNTXBuy Now
Context Therapeutics
$1.76155.68% → $4.5Initiates → OverweightGet Alert
04/29/2024IBRXBuy Now
ImmunityBio
$7.88-23.86%$5 → $6MaintainsNeutralGet Alert
04/25/2024ACRVBuy Now
Acrivon Therapeutics
$8.74243.25%$26 → $30MaintainsOverweightGet Alert
04/22/2024BOLDBuy Now
Boundless Bio
$9.72105.76% → $20Initiates → OverweightGet Alert
04/05/2024ACHLBuy Now
Achilles Therapeutics
$0.90122.22%$8 → $2DowngradeOverweight → NeutralGet Alert
03/27/2024KROSBuy Now
Keros Therapeutics
$53.2797.11% → $105MaintainsOverweightGet Alert
03/27/2024LENZBuy Now
LENZ Therapeutics
$15.8576.66% → $28Initiates → OverweightGet Alert
03/26/2024DAWNBuy Now
Day One Biopharmaceutical
$16.12148.14%$40 → $40MaintainsOverweightGet Alert
03/25/2024IBRXBuy Now
ImmunityBio
$7.88-36.55%$4 → $5MaintainsNeutralGet Alert
03/18/2024IMABBuy Now
I-MAB
$1.76467.54%$15 → $10MaintainsOverweightGet Alert
03/14/2024IOVABuy Now
Iovance Biotherapeutics
$10.7077.65%$18 → $19MaintainsOverweightGet Alert
03/11/2024RVMDBuy Now
Revolution Medicines
$38.9910.28% → $43Initiates → OverweightGet Alert
03/01/2024CRDFBuy Now
Cardiff Oncology
$3.6492.31%$5 → $7MaintainsOverweightGet Alert
02/29/2024SDGRBuy Now
Schrodinger
$22.80119.3%$60 → $50MaintainsOverweightGet Alert
02/28/2024DAWNBuy Now
Day One Biopharmaceutical
$16.12148.14%$45 → $40MaintainsOverweightGet Alert
02/26/2024OCULBuy Now
Ocular Therapeutix
$5.99150.42%$10 → $15MaintainsOverweightGet Alert
02/20/2024IOVABuy Now
Iovance Biotherapeutics
$10.7068.3%$14 → $18MaintainsOverweightGet Alert
02/12/2024TNGXBuy Now
Tango Therapeutics
$7.67134.68% → $18Initiates → OverweightGet Alert
12/27/2023GRCLBuy Now
Gracell Biotechnologies
—— → $10DowngradeOverweight → NeutralGet Alert
12/15/2023AADIBuy Now
Aadi Bioscience
$1.86168.82%$30 → $5MaintainsOverweightGet Alert
12/04/2023IMGNBuy Now
Immunogen
——$24 → $31DowngradeOverweight → NeutralGet Alert
10/16/2023RPTXBuy Now
Repare Therapeutics
$3.53608.22%$30 → $25MaintainsOverweightGet Alert
10/10/2023MRTXBuy Now
Mirati Therapeutics
—— → $58DowngradeOverweight → NeutralGet Alert
08/15/2023TSBXBuy Now
Turnstone Biologics
$2.80614.29% → $20Initiates → OverweightGet Alert
07/24/2023GILDBuy Now
Gilead Sciences
$67.2148.79%$105 → $100MaintainsOverweightGet Alert
07/14/2023BDTXBuy Now
Black Diamond Therapeutic
$5.27108.73% → $11Initiates → OverweightGet Alert
06/26/2023BMEABuy Now
Biomea Fusion
$13.12242.99%$40 → $45MaintainsOverweightGet Alert
05/23/2023RAINBuy Now
Rain Oncology
——$15 → $1.75DowngradeOverweight → NeutralGet Alert
05/12/2023IBRXBuy Now
ImmunityBio
$7.88-49.24%$10 → $4DowngradeOverweight → NeutralGet Alert
05/10/2023EXELBuy Now
Exelixis
$20.9633.59% → $28Assumes → OverweightGet Alert
05/10/2023HALOBuy Now
Halozyme Therapeutics
$45.870.29% → $46UpgradeNeutral → OverweightGet Alert
05/05/2023SDGRBuy Now
Schrodinger
$22.80163.16% → $60Assumes → OverweightGet Alert
05/05/2023KROSBuy Now
Keros Therapeutics
$53.27106.5%$120 → $110MaintainsOverweightGet Alert
05/03/2023IMGNBuy Now
Immunogen
——$6 → $16UpgradeNeutral → OverweightGet Alert
04/28/2023GILDBuy Now
Gilead Sciences
$67.2156.23% → $105Assumes → OverweightGet Alert
04/03/2023IMABBuy Now
I-MAB
$1.761318.84%$30 → $25MaintainsOverweightGet Alert
03/28/2023BMEABuy Now
Biomea Fusion
$13.12204.88%$16 → $40MaintainsOverweightGet Alert
01/27/2023IOVABuy Now
Iovance Biotherapeutics
$10.7030.9%$11 → $14UpgradeNeutral → OverweightGet Alert
01/09/2023DAWNBuy Now
Day One Biopharmaceutical
$16.12179.16%$40 → $45MaintainsOverweightGet Alert
12/20/2022CPRXBuy Now
Catalyst Pharmaceuticals
$16.7619.33%$18 → $20MaintainsOverweightGet Alert
12/12/2022ACRVBuy Now
Acrivon Therapeutics
$8.74186.04% → $25Initiates → OverweightGet Alert
12/07/2022ACHLBuy Now
Achilles Therapeutics
$0.90788.89%$10 → $8MaintainsOverweightGet Alert
11/21/2022IOVABuy Now
Iovance Biotherapeutics
$10.702.85%$13 → $11MaintainsNeutralGet Alert
11/08/2022OYSTBuy Now
Oyster Point Pharma
——$15 → $11DowngradeOverweight → NeutralGet Alert
09/13/2022CRDFBuy Now
Cardiff Oncology
$3.6437.36%$7 → $5MaintainsOverweightGet Alert
08/30/2022IMABBuy Now
I-MAB
$1.761602.61%$35 → $30MaintainsOverweightGet Alert
08/11/2022HARPBuy Now
Harpoon Therapeutics
——$90 → $70MaintainsOverweightGet Alert
07/07/2022CTMXBuy Now
CytomX Therapeutics
$1.99-24.62%$10 → $1.5DowngradeOverweight → NeutralGet Alert
06/21/2022DAWNBuy Now
Day One Biopharmaceutical
$16.12148.14%$35 → $40MaintainsOverweightGet Alert
06/02/2022RPTXBuy Now
Repare Therapeutics
$3.53749.86%$25 → $30MaintainsOverweightGet Alert
05/27/2022IOVABuy Now
Iovance Biotherapeutics
$10.7021.55%$20 → $13MaintainsNeutralGet Alert
05/12/2022EPIXBuy Now
ESSA Pharma
$6.00233.33%$50 → $20MaintainsOverweightGet Alert
05/10/2022OCULBuy Now
Ocular Therapeutix
$5.99167.11%$20 → $16MaintainsOverweightGet Alert
05/05/2022CNTBBuy Now
Connect Biopharma Hldgs
$1.85-18.92%$25 → $1.5DowngradeOverweight → NeutralGet Alert
03/14/2022HARPBuy Now
Harpoon Therapeutics
——$270 → $150MaintainsOverweightGet Alert
03/10/2022SNSEBuy Now
Sensei Biotherapeutics
$1.59528.93%$12 → $10MaintainsOverweightGet Alert
03/02/2022NLTXBuy Now
Neoleukin Therapeutics
——$600 → $500MaintainsOverweightGet Alert

Recent Analyst Stock Rating News

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Decoding 6 Analyst Evaluations For Ocular Therapeutix
Critical Insights From Schrodinger Analyst Ratings: What You Need To Know
Analyst Expectations For Mirati Therapeutics's Future
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $
What's Going On With Biomea Fusion Stock?
Biomea Fusion Inc (NASDAQ: BMEA) shares are trading higher. The company reported fourth-quarter results after the bell and announced an offering Wednesday morning. Several analysts are out with positive coverage.
Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings
Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation
Seattle Genetics, Inc’s (NASDAQ: SGEN) stock already reflects the urothelial bladder cancer opportunity, according to Piper Sandler.
Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free